IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	Group Art Unit: 1633
BODARY-WINTER, SARAH et al.	Examiner: LEAVITT, MARIA GOMEZ
Serial No.: 10/527,100	Confirmation No: 3801
Filed: March 9, 2005	Customer No: 09157
Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES	Electronically filed on: November 17, 2006

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 C.F.R. §1.121

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated September 19, 2006, please consider the following election and remarks. This response is timely filed with a Petition And Fees For One Month Extension Of Time and fees to include November 19, 2006.

Election:

Applicants received a Communication from the U.S. Patent and Trademark Office dated September 19, 2006 which contained a requirement for restriction in connection with the application captioned above. More specifically, the Examiner has required a restriction under 35 U.S.C. § 121 and 372 of one of the following inventions:

Group I: A nucleotide sequence of claim 1 - 3 and 9.

Group II: A chimeric molecule comprising a polypeptide as recited in claims 1-3 and 9.

Group III: An antibody against a polypeptide sequence as recited in claim 1-3 and 9.

Group IV: An agonist of said polypeptide polypeptide sequence as recited in claim 1-3 and 9.

Group V: An antagonist of said polypeptide polypeptide sequence as recited in claim 1-3 and 9.

Group VI: Claims 1, 2, 3, 4-8, 9, 18-19 drawn to an isolated nucleic acid encoding the polypeptide, a recombinant expression vector comprising said sequence, a host cell comprising said vector, a process for producing said polypeptide using said host cell and said isolated polypeptide and a method for treating an immune related disorder in a mammal by administering said polypeptide.

Group VII: Claims 9-11, 14-16, and 17 drawn to an isolated polypeptide, a chimeric molecule comprising said polypeptide, a composition and an article of manufacture comprising said polypeptide.

Group VIII: Claims 12-16 and 17 drawn to an antibody, which specifically binds a polypeptide, a composition comprising and an article of manufacture comprising said

Group IX: A method comprising the presence of a PRO polypeptide.

Group X: A method comprising the presence of gene encoding a PRO polypeptide.

Group XI: A method comprising the presence of an anti PRO polypeptide antibody.

Group XII: A method comprising the presence of an inhibitor of a gene encoding a PRO polypeptide.

Group XIII: A method comprising the presence of an antagonist of a PRO polypeptide.

Group XIV: Claims 20 and 22 drawn to a method for determining the presence of a PRO polypeptide by contacting a sample with an antibody selected form the Markush group of claim 20.

Group XV: Claims 21 and 28 drawn to a method for diagnosing an immune related disease in a mammal detecting the level of a gene using a nucleic acid probe.

Group XVI: Claims 23 drawn to a method for diagnosing an immune related disease in a mammal, by using a polypeptide.

Group XVII: Claims 24-26 drawn to a method for identifying a compound using cell expressing the polypeptide.

Group XVIII: Claim 27 drawn to a method for stimulating an immune response using a polypeptide agonist.

Applicants hereby elect to prosecute the invention of Group X with respect to PRO71202, which corresponds with SEQ ID NO:1. As further required by the Requirement for Restriction, Applicants also elect to prosecute the invention of Group XV, which corresponds with Claims 21 and 28, also with respect to PRO71202 (SEQ ID NO:1).